Blood Journal
Leading the way in experimental and clinical research in hematology

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial

  1. Tanzina Haque1,
  2. Gwen M. Wilkie1,
  3. Marie M. Jones1,
  4. Craig D. Higgins2,
  5. Gillian Urquhart1,
  6. Phoebe Wingate1,
  7. David Burns1,
  8. Karen McAulay1,
  9. Marc Turner3,
  10. Christopher Bellamy4,
  11. Peter L. Amlot5,
  12. Deirdre Kelly6,
  13. Alastair MacGilchrist7,
  14. Maher K. Gandhi8,
  15. Anthony J. Swerdlow2, and
  16. Dorothy H. Crawford1
  1. 1Clinical and Molecular Virology Laboratory, University of Edinburgh, Edinburgh, United Kingdom;
  2. 2Sir Richard Doll Building, Institute of Cancer Research, Sutton, United Kingdom;
  3. 3Scottish National Blood Transfusion Service, Royal Infirmary, Edinburgh, United Kingdom;
  4. 4Department of Pathology, Royal Infirmary, Edinburgh, United Kingdom;
  5. 5Department of Immunology, Royal Free Hospital and University College Medical School, London, United Kingdom;
  6. 6Liver Unit, Birmingham Children's Hospital, Birmingham, United Kingdom;
  7. 7Liver Transplant Unit, Edinburgh Royal Infirmary, Edinburgh, United Kingdom,
  8. 8Immunohaematology Laboratory, Queensland Institute of Medical Research, Brisbane, Australia
PDF Container